Literature DB >> 6714285

Pharmacokinetics of nadolol in healthy subjects.

M Schäfer-Korting, N Bach, H Knauf, E Mutschler.   

Abstract

In 7 healthy subjects (3 males and 4 females), the kinetics of nadolol was investigated after oral doses of 60 and 120 mg. The t 1/2 was 14.0 +/- 1.8 h. The peak plasma level was doubled on doubling the dose (from 69 +/- 15 to 132 +/- 27 ng/ml, respectively) and the urinary excretion (13.5%) rose similarly. The half-life of elimination was longer at night than in the day, probably because of the slower nocturnal flow of urine.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6714285     DOI: 10.1007/bf00546720

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  9 in total

1.  Pharmacokinetics of beta-receptor-blocking agents in relation to their anti-hypertensive effect.

Authors:  R Gugler; G Bodem; H J Dengler
Journal:  Clin Sci Mol Med Suppl       Date:  1976-12

2.  Pharmacology of nadolol (SQ 11725), a beta-adrenergic antagonist lacking direct myocardial depression.

Authors:  R J Lee; D B Evans; S H Baky; R J Laffan
Journal:  Eur J Pharmacol       Date:  1975 Sep-Oct       Impact factor: 4.432

3.  Absorption of the beta-adrenergic-blocking agent, nadolol, by mice, rats, hamsters, rabbits, dogs, monkeys, and man: an unusual species difference.

Authors:  J Dreyfuss; J M Shaw; J J Ross
Journal:  Xenobiotica       Date:  1978-08       Impact factor: 1.908

4.  Pharmacokinetics of nadolol, a beta-receptor antagonist: administration of therapeutic single- and multiple-dosage regimens to hypertensive patients.

Authors:  J Dreyfuss; D L Griffith; S M Singhvi; J M Shaw; J J Ross; R A Vukovich; D A Willard
Journal:  J Clin Pharmacol       Date:  1979 Nov-Dec       Impact factor: 3.126

5.  Fluorodensitometric determination of nadolol in plasma and urine.

Authors:  M Schäfer-Korting; E Mutschler
Journal:  J Chromatogr       Date:  1982-07-09

6.  Simultaneous tubular excretion and reabsorption of pindolol in man.

Authors:  L Balant; K Muir; P Dayer; A Gorgia; J L Eberlin; J Estreicher; J Fabre
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

7.  Angina pectoris: effective therapy once daily.

Authors:  G Prager
Journal:  J Int Med Res       Date:  1979       Impact factor: 1.671

Review 8.  Clinical pharmacokinetics of beta-adrenoreceptor blocking drugs.

Authors:  G Johnsson; C G Regàrdh
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

9.  Studies on the pharmacokinetics and pharmacodynamics of atenolol in man.

Authors:  J D Fitzgerald; R Ruffin; K G Smedstad; R Roberts; J McAinsh
Journal:  Eur J Clin Pharmacol       Date:  1978-05-17       Impact factor: 2.953

  9 in total
  6 in total

Review 1.  Pharmacokinetic Variability of Drugs Used for Prophylactic Treatment of Migraine.

Authors:  Peer Tfelt-Hansen; Frederik Nybye Ågesen; Agniezka Pavbro; Jacob Tfelt-Hansen
Journal:  CNS Drugs       Date:  2017-05       Impact factor: 5.749

2.  Multi-functional scaling methodology for translational pharmacokinetic and pharmacodynamic applications using integrated microphysiological systems (MPS).

Authors:  Christian Maass; Cynthia L Stokes; Linda G Griffith; Murat Cirit
Journal:  Integr Biol (Camb)       Date:  2017-04-18       Impact factor: 2.192

3.  Bioequivalence of a highly variable drug: an experience with nadolol.

Authors:  R G Buice; V S Subramanian; K L Duchin; S Uko-Nne
Journal:  Pharm Res       Date:  1996-07       Impact factor: 4.200

4.  Plasma IL-12 levels are suppressed in vivo by stress and surgery through endogenous release of glucocorticoids and prostaglandins but not catecholamines or opioids.

Authors:  Lee Shaashua; Ella Rosenne; Elad Neeman; Liat Sorski; Luba Sominsky; Pini Matzner; Gayle G Page; Shamgar Ben-Eliyahu
Journal:  Psychoneuroendocrinology       Date:  2014-01-07       Impact factor: 4.905

5.  Vigorous exercise mobilizes CD34+ hematopoietic stem cells to peripheral blood via the β2-adrenergic receptor.

Authors:  Nadia H Agha; Forrest L Baker; Hawley E Kunz; Rachel Graff; Rod Azadan; Chad Dolan; Mitzi S Laughlin; Chitra Hosing; Melissa M Markofski; Richard A Bond; Catherine M Bollard; Richard J Simpson
Journal:  Brain Behav Immun       Date:  2017-10-07       Impact factor: 7.217

6.  The Effect of Excipients on the Permeability of BCS Class III Compounds and Implications for Biowaivers.

Authors:  Alan Parr; Ismael J Hidalgo; Chris Bode; William Brown; Mehran Yazdanian; Mario A Gonzalez; Kazuko Sagawa; Kevin Miller; Wenlei Jiang; Erika S Stippler
Journal:  Pharm Res       Date:  2015-08-19       Impact factor: 4.200

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.